October 3rd 2024
Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it priority review.
September 20th 2024
September 19th 2024
September 18th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Liso-Cel Achieves High MRD Negativity Rate in High-Risk CLL/SLL
December 8th 2020Chimeric antigen receptor T-cell therapy with lisocabtagene maraleucel led to rapid and durable responses in patients with high-risk relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More
Orca-T Shows Preventative Potential for GVHS in High-Risk Blood Cancers
December 6th 2020The precision Treg-engineered donor product Orca-T exhibited preventive potential for graft-versus-host disease in patients with high-risk hematologic malignancies who underwent hematopietic stem cell transplantation, with less immunosuppression compared with the standard of care.
Read More
High-/Low-Dose Sabatolimab Exhibit Comparable Pharmacokinetics in MDS and AML
December 6th 2020In patients with acute myeloid leukemia and myelodysplastic syndrome, treatment with sabatolimab administered at 200 mg every 2 weeks and 800 mg every 4 weeks demonstrated similar pharmacokinetic activity, according to findings from a dose-selection and dose-response analysis presented during the 2020 American Society of Hematology Annual Meeting.
Read More
UCART22 Safe and Active in CD22-Expressing B-Cell ALLs
December 6th 2020Early signs of clinical activity were observed in adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia who were treated with an investigational allogeneic off-the-shelf CD22-directed therapy.
Read More
Novel BCMA-Targeted Immunotherapy Demonstrates Safety, Convenience in Relapsed/Refractory Myeloma
December 6th 2020A novel BCMA and CD3 targeted bispecific T-cell engaging immunotherapy agent TNB-383B has demonstrated significant responses at higher dose levels and tolerability at all dose levels, including mild cases of cytokine release syndrome, according to initial results of a phase 1 trial presented during the 2020 American Society of Hematology Annual Meeting.
Read More
Natural Killer Cell Proliferation Achieved in MDS/AML With Novel TriKE
December 6th 2020Treatment with a novel tri-specific natural killer cell engager agent led to natural killer cell proliferation across dose levels in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia.
Read More
Overall Survival in High-Risk Myelofibrosis Improved With High-Dose Imetelstat
December 5th 2020Higher doses of telomerase inhibitor imetelstat demonstrated better overall survival, spleen response, and symptom response in patients with myelofibrosis who are relapsed after or refractory to therapy with Janus kinase inhibitors in the phase 2 IMbark study.
Read More
Phase 3 Trial Shows More Efficacy With Ruxolitinib Than Best Available Therapy in Chronic GVHD
December 5th 2020The phase 3 REACH3 trial of ruxolitinib in patients with chronic graft-versus-host disease with an inadequate response to corticosteroids demonstrated significantly higher overall response rate, a substantially greater improvement in failure-free survival, and greater symptom improvement compared with best available therapy.
Read More
FDA Grants Priority Review to Belumosudil for Chronic Graft-Versus-Host Disease
November 30th 2020The FDA accepted the New Drug Application from belumosudil and granted it a Priority Review designation for the treatment of patients with chronic graft-versus-host disease. The Prescription Drug User Fee Act target action date has been set to May 30, 2021.
Read More
Clinical Trials Are Underway on Novel Approaches to CML-Resistant BCR-ABL1 Inhibitors
November 27th 2020Agents with novel mechanisms of action distinct from available ATP-competitive tyrosine kinase inhibitors have been tested in patients with previously treated, Philadelphia chromosome–positive chronic myeloid leukemia and offer promise to facilitate deeper remissions.
Read More
Novel Assay Identifies Mutations, Fusions, Exon Skipping in Myeloid and Lymphoid Malignancies
November 20th 2020In an interview with Targeted Oncology during the Association for Molecular Pathology 2020 Annual Meeting, Rachel Sparks, MD, discussed the findings observed in hematologic malignancies with the use of a new RNA-based NGS assay.
Read More
FDA Grants Fast Track Designation to Rilzabrutinib for Treatment of Immune Thrombocytopenia
November 18th 2020The FDA has granted a Fast Track designation to rilzabrutinib, an oral investigational Bruton’s tyrosine kinase inhibitor, for the treatment of immune thrombocytopenia. The drug was previously granted Orphan Drug designation for this indication.
Read More
Sequencing TP53 Mutations in Myeloid Neoplasms
November 17th 2020Routine testing for the presence of TP53 mutations in myeloid neoplasms by sequencing will become an important part of routine care as TP53-targeting agents become available, according to a poster presented at the Association for Molecular Pathology 2020 Annual Meeting and Expo.
Read More
The Possibilities in AML With the FDA Approval of Azacitidine and Venetoclax
November 16th 2020Brain A. Jonas, MD, discusses the future of treatment for older patients with acute myeloid leukemia, now that the FDA has granted approval to azacitidine plus venetoclax for patients aged 75 years or older.
Watch
Azacitidine/Venetoclax Represents New Gold Standard for Older Patients with Treatment-Naïve AML
November 13th 2020In an interview with Targeted Oncology following the announcement of the FDA approval of azacitidine plus venetoclax in older patients with acute myeloid leukemia, Brian Jonas, MD, provided insight on the VILAE-A study results. He also gave expert advice on how to approach treating older patients with acute myeloid leukemia in every day practice.
Read More
Outcomes in Lower-Risk MDS Advance As Novel Strategies Emerge
November 4th 2020Outcomes for patients with myelodysplastic syndrome range from a median of 5.3 years in the lower-risk population to 8.4 months among patient with very high-risk disease. These outcomes are changing as novel therapies for the lower-risk population enter the treatment landscape.
Read More